nach oben

Current Hepatology Reports

Erschienen in:

18.01.2024

Endocrinology for the Hepatologist

verfasst von: Scott Isaacs, Arabella Isaacs

Erschienen in: Current Hepatology Reports | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

The purpose of this review is to discuss endocrine diseases that affect the liver and how chronic liver disease affects endocrine function.

Recent findings

Over the past 2 decades, we have gained an expanding knowledge of the liver as an endocrine organ. There have been numerous discoveries in hepatic hormone and hepatokine synthesis, metabolism, and production of hormone binding proteins. Global awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing as the most common cause of chronic liver disease, and its mutually detrimental relationship with type 2 diabetes (T2D), lipotoxicity, insulin resistance and the metabolic syndrome. Recent discoveries have elucidated mechanisms and a better understanding of cirrhosis-associated endocrinopathies.

Summary

The liver facilitates numerous endocrine functions and is a dynamic component of the endocrine system. This review will discuss endocrine disorders including diabetes, polycystic ovary syndrome (PCOS), thyroid disorders, adrenal insufficiency, growth hormone deficiency, osteosarcopenia, and male hypogonadism and the relationship to chronic liver disease.

Lu Y, Zheng MH, Wang H. Are hepatocytes endocrine cells? Metab Target Organ Damage 2023;3:3. https://doi.org/10.20517/mtod.2023.11

Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017 Nov 6;27(21):R1147-R1151. doi: https://doi.org/10.1016/j.cub.2017.09.019. PMID: 29112863; PMCID: PMC5897118

Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40(5):1367–93. https://doi.org/10.1210/er.2019-00034. (PMID: 31098621).CrossRefPubMed

Nemeth E, Ganz T. Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis. Int J Mol Sci. 2021 Jun 17;22(12):6493. doi: https://doi.org/10.3390/ijms22126493. PMID: 34204327; PMCID: PMC8235187

Reinehr T, Roth CL. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J Clin Endocrinol Metab. 2008;93(11):4479–85. https://doi.org/10.1210/jc.2008-1505. (Epub 2008 Aug 26 PMID: 18728159).CrossRefPubMed

Mori K, Emoto M, Araki T, Yokoyama H, Lee E, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism. 2008;57(9):1248–52. https://doi.org/10.1016/j.metabol.2008.04.019. (PMID: 18702951).CrossRefPubMed

Chekol Abebe E, Tilahun Muche Z, Behaile T/Mariam A, Mengie Ayele T, Mekonnen Agidew M, Teshome Azezew M, Abebe Zewde E, Asmamaw Dejenie T, Asmamaw Mengstie M. The structure, biosynthesis, and biological roles of fetuin-A: A review. Front Cell Dev Biol. 2022 Jul 18;10:945287. doi: https://doi.org/10.3389/fcell.2022.945287. PMID: 35923855; PMCID: PMC9340150.

Meex RC, Hoy AJ, Morris A, Brown RD, Lo JC, Burke M, Goode RJ, Kingwell BA, Kraakman MJ, Febbraio MA, Greve JW, Rensen SS, Molloy MP, Lancaster GI, Bruce CR, Watt MJ. Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to Impaired Glucose Metabolism. Cell Metab. 2015;22(6):1078–89. https://doi.org/10.1016/j.cmet.2015.09.023. (Epub 2015 Oct 22 PMID: 26603189).CrossRefPubMed

Stefan N, Schick F, Birkenfeld AL, Häring HU, White MF. The role of hepatokines in NAFLD. Cell Metab. 2023 Feb 7;35(2):236-252. doi: https://doi.org/10.1016/j.cmet.2023.01.006. PMID: 36754018; PMCID: PMC10157895

10.

Kharitonenkov A, Adams AC. Inventing new medicines: The FGF21 story. Mol Metab. 2013 Dec 27;3(3):221-9. doi: https://doi.org/10.1016/j.molmet.2023.12.003. PMID: 24749049; PMCID: PMC3986619

11.

Jensen-Cody SO, Potthoff MJ. Hepatokines and metabolism: Deciphering communication from the liver. Mol Metab. 2021 Feb;44:101138. doi: https://doi.org/10.1016/j.molmet.2020.101138. Epub 2020 Dec 4. PMID: 33285302; PMCID: PMC7788242.

12.

Szczepańska E, Gietka-Czernel M. FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance. Horm Metab Res. 2022;54(4):203–11. https://doi.org/10.1055/a-1778-4159. (Epub 2022 Apr 12 PMID: 35413740).CrossRefPubMed

13.

Luo F, Das A, Khetarpal SA, Fang Z, Zelniker TA, Rosenson RS, Qamar A. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. Trends Cardiovasc Med. 2023 Feb 5:S1050–1738(23)00018-X. doi: https://doi.org/10.1016/j.tcm.2023.01.008. Epub ahead of print. PMID: 36746257.

14.

Steinbrenner H, Duntas LH, Rayman MP. The role of selenium in type-2 diabetes mellitus and its metabolic comorbidities. Redox Biol. 2022 Apr;50:102236. doi: https://doi.org/10.1016/j.redox.2022.102236. Epub 2022 Jan 24. PMID: 35144052; PMCID: PMC8844812.

15.

Hansen JS, Plomgaard P. Circulating follistatin in relation to energy metabolism. Mol Cell Endocrinol. 2016;15(433):87–93. https://doi.org/10.1016/j.mce.2016.06.002. (Epub 2016 Jun 2 PMID: 27264073).CrossRef

16.

Tao R, Wang C, Stöhr O, Qiu W, Hu Y, Miao J, Dong XC, Leng S, Stefater M, Stylopoulos N, Lin L, Copps KD, White MF. Inactivating hepatic follistatin alleviates hyperglycemia. Nat Med. 2018 Jul;24(7):1058–1069. doi: https://doi.org/10.1038/s41591-018-0048-0. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Oct;24(10):1628. PMID: 29867232; PMCID: PMC6039237.

17.

Isaacs S. Nonalcoholic Fatty Liver Disease. Endocrinol Metab Clin North Am. 2023;52(1):149–64. https://doi.org/10.1016/j.ecl.2022.06.007. (Epub 2022 Nov 18 PMID: 36754491).CrossRefPubMed

18••.

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne C, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer D, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot B, Korenjak M, Kowdley K, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell E, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wai-Sun Wong V, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023 Jun 20:S0168–8278(23)00418-X. doi: https://doi.org/10.1016/j.jhep.2023.06.003. Epub ahead of print. PMID: 37364790. Important consensus statement on the new nomenclature for fatty/steatotic liver disease.

19••.

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022 May;28(5):528-562. doi: https://doi.org/10.1016/j.eprac.2022.03.010. PMID: 35569886. Important evidence-based clinical guidelines by the American Association of Clinical Endocrinology highlighting the link between steatotic liver disease and cardiometabolic diseases

20.

Younossi Z, Alkhouri N, Cusi K, Isaacs S, Kanwal F, Noureddin M, Loomba R, Ravendhran N, Lam B, Nader K, Racila A, Nader F, Henry L. A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2023;57(3):304–12. https://doi.org/10.1111/apt.17346. (Epub 2022 Dec 13 PMID: 36511349).CrossRefPubMed

21•.

Harrison SA, Gawrieh S, Roberts K, Lisanti CJ, Schwope RB, Cebe KM, Paradis V, Bedossa P, Aldridge Whitehead JM, Labourdette A, Miette V, Neubauer S, Fournier C, Paredes AH, Alkhouri N. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021 Aug;75(2):284-291. doi: https://doi.org/10.1016/j.jhep.2021.02.034. Epub 2021 Mar 18. PMID: 33746083. Important prospective study of the prevalence of steatotic liver disease in a middle-aged cohort in the U.S.

22.

Younossi ZM, Henry L, Isaacs S, Cusi K. Identification of High Risk NAFLD Patients in Endocrinology Clinics. Endocr Pract. 2023 Jul 3:S1530–891X(23)00469-X. doi: https://doi.org/10.1016/j.eprac.2023.06.012. Epub ahead of print. PMID: 37406857.

23.

Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity (Silver Spring). 2021 Nov;29(11):1950–1960. doi: https://doi.org/10.1002/oby.23263. Epub 2021 Sep 23. PMID: 34553836; PMCID: PMC9290591.

24.

Budd J, Cusi K. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Curr Diab Rep. 2020;20(11):59. https://doi.org/10.1007/s11892-020-01349-1. (PMID: 33015726).CrossRefPubMed

25.

Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, Portillo Romero J, Schmidt S, Chang KL, Samraj G, Malaty J, Huber K, Bedossa P, Kalavalapalli S, Marte J, Barb D, Poulton D, Fanous N, Cusi K. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care. 2021 Feb;44(2):399–406. doi: https://doi.org/10.2337/dc20-1997. Epub 2020 Dec 21. PMID: 33355256; PMCID: PMC7818321.

26.

Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, Madamba E, Bettencourt R, Richards L, Behling C, Sirlin CB, Loomba R. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023 Mar;78(3):471–478. doi: https://doi.org/10.1016/j.jhep.2022.11.010. Epub 2022 Nov 19. PMID: 36410554; PMCID: PMC9975077.

27••.

Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021 May 13;184(10):2537-2564. doi: https://doi.org/10.1016/j.cell.2021.04.015. PMID: 33989548. Important review of the pathophysiology and natural history of steatotic liver disease.

28.

Corbin KD, Driscoll KA, Pratley RE, Smith SR, Maahs DM, Mayer-Davis EJ; Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON). Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. Endocr Rev. 2018 Oct 1;39(5):629–663. doi: https://doi.org/10.1210/er.2017-00191. PMID: 30060120.

29.

de Vries M, Westerink J, Kaasjager KHAH, de Valk HW. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105(12): 3842e3853.

30.

Cusi K, Sanyal AJ, Zhang S, et al. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. 2017;19(11):1630e1634.

31.

Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017 May;65(5):1557–1565. doi: https://doi.org/10.1002/hep.29085. Epub 2017 Mar 31. PMID: 28130788; PMCID: PMC5397356.

32.

Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, Isaacs SD, Izuora KE, Low Wang CC, Twining CL, Umpierrez GE, Valencia WM. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023 May;29(5):305-340. doi: https://doi.org/10.1016/j.eprac.2023.02.001. Erratum in: Endocr Pract. 2023 Sep;29(9):746. Erratum in: Endocr Pract. 2023 Dec;29(12):1025. PMID: 37150579

33.

Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393–406. https://doi.org/10.1016/S2213-8587(22)00070-5. (Epub 2022 Apr 22 PMID: 35468325).CrossRefPubMed

34.

Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, Alkhouri N, Bashir MR. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023 Nov;29(11):2919–2928. doi: https://doi.org/10.1038/s41591-023-02603-1. Epub 2023 Oct 16. PMID: 37845512; PMCID: PMC10667098.

35.

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. https://doi.org/10.1038/nrgastro.2017.109. (Epub 2017 Sep 20 PMID: 28930295).CrossRefPubMed

36.

Simon TG, Roelstraete B, Alkhouri N, Hagström H, Sundström J, Ludvigsson JF. Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease. Gut. 2023;72(3):573–80. https://doi.org/10.1136/gutjnl-2022-328105. (Epub 2022 Dec 15 PMID: 36522149).CrossRefPubMed

37.

Falzarano C, Lofton T, Osei-Ntansah A, Oliver T, Southward T, Stewart S, Andrisse S. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2022;107(1):258–72. https://doi.org/10.1210/clinem/dgab658. (PMID: 34491336).CrossRefPubMed

38.

Vidal-Cevallos P, Mijangos-Trejo A, Uribe M, Tapia NC. The Interlink Between Metabolic-Associated Fatty Liver Disease and Polycystic Ovary Syndrome. Endocrinol Metab Clin North Am. 2023;52(3):533–45. https://doi.org/10.1016/j.ecl.2023.01.005. (Epub 2023 Mar 15 PMID: 37495343).CrossRefPubMed

39.

Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, Yamamoto M, Suda K, Takahashi M, Seo Y, Yano Y, Kitazawa R, Kitazawa S, Koga M, Okimura Y, Chihara K, Takahashi Y. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol. 2012;167(1):67–74. https://doi.org/10.1530/EJE-12-0252. (Epub 2012 Apr 24 PMID: 22535644).CrossRefPubMed

40.

Dichtel LE, Corey KE, Haines MS, Chicote ML, Lee H, Kimball A, Colling C, Simon TG, Long MT, Husseini J, Bredella MA, Miller KK. Growth hormone administration improves nonalcoholic fatty liver disease in overweight/obesity: a randomized trial. J Clin Endocrinol Metab. 2023 Jun 28:dgad375. doi: https://doi.org/10.1210/clinem/dgad375. Epub ahead of print. PMID: 37379033.

41.

Sumida Y, Yonei Y, Tanaka S, Mori K, Kanemasa K, Imai S, Taketani H, Hara T, Seko Y, Ishiba H, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, Minami M, Itoh Y. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease. Hepatol Res. 2015;45(7):771–81. https://doi.org/10.1111/hepr.12408. (Epub 2014 Sep 30 PMID: 25163357).CrossRefPubMed

42.

Xu L, Xu C, Yu C, Miao M, Zhang X, Zhu Z, Ding X, Li Y. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS One. 2012;7(8):e44136. doi: https://doi.org/10.1371/journal.pone.0044136. Epub 2012 Aug 31. PMID: 22952901; PMCID: PMC3432067.

43.

Dichtel LE, Cordoba-Chacon J, Kineman RD. Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2022 Jun 16;107(7):1812-1824. doi: https://doi.org/10.1210/clinem/dgac088. PMID: 35172328; PMCID: PMC9202731

44••.

Ritter MJ, Amano I, Hollenberg AN. Thyroid Hormone Signaling and the Liver. Hepatology. 2020 Aug;72(2):742-752. Important review of thyroid hormone signaling and lipid metabolism in the liver.

45.

Mantovani A, Nascimbeni F, Lonardo A, Zoppini G, Bonora E, Mantzoros CS, Targher G. Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Thyroid. 2018;28(10):1270–84. https://doi.org/10.1089/thy.2018.0257. (Epub 2018 Aug 30 PMID: 30084737).CrossRefPubMed

46.

Kim D, Vazquez-Montesino LM, Escober JA, Fernandes CT, Cholankeril G, Loomba R, Harrison SA, Younossi ZM, Ahmed A. Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. Am J Gastroenterol. 2020;115(9):1496–504. https://doi.org/10.14309/ajg.0000000000000654. (PMID: 32496342).CrossRefPubMed

47.

Tang Q, Zeng M, Chen L, Fu N. Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases. Front Pharmacol. 2022 Jun 2;13:871100. doi: https://doi.org/10.3389/fphar.2022.871100. PMID: 35721201; PMCID: PMC9201453

48.

Yorke E. Hyperthyroidism and Liver Dysfunction: A Review of a Common Comorbidity. Clin Med Insights Endocrinol Diabetes. 2022 Feb 7;15:11795514221074672. doi: https://doi.org/10.1177/11795514221074672. PMID: 35153522; PMCID: PMC8829710

49.

Hatziagelaki E, Paschou SA, Schön M, Psaltopoulou T, Roden M. NAFLD and thyroid function: pathophysiological and therapeutic considerations. Trends Endocrinol Metab. 2022;33(11):755–68. https://doi.org/10.1016/j.tem.2022.08.001. (Epub 2022 Sep 26 PMID: 36171155).CrossRefPubMed

50.

Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012 Nov-Dec;18(6):988–1028. doi: https://doi.org/10.4158/EP12280.GL. Erratum in: Endocr Pract. 2013 Jan-Feb;19(1):175. PMID: 23246686.

51.

Bekkering GE, Agoritsas T, Lytvyn L, Heen AF, Feller M, Moutzouri E, Abdulazeem H, Aertgeerts B, Beecher D, Brito JP, Farhoumand PD, Singh Ospina N, Rodondi N, van Driel M, Wallace E, Snel M, Okwen PM, Siemieniuk R, Vandvik PO, Kuijpers T, Vermandere M. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019;14(365):l2006. https://doi.org/10.1136/bmj.l2006. (PMID: 31088853).CrossRef

52.

Piantanida E, Ippolito S, Gallo D, Masiello E, Premoli P, Cusini C, Rosetti S, Sabatino J, Segato S, Trimarchi F, Bartalena L, Tanda ML. The interplay between thyroid and liver: implications for clinical practice. J Endocrinol Invest. 2020;43(7):885–99. https://doi.org/10.1007/s40618-020-01208-6. (Epub 2020 Mar 12 PMID: 32166702).CrossRefPubMed

53.

Wang L, Yu W, Cao W, Lu W. The abnormality of thyroid hormones in patients with type A hepatic encephalopathy. Oncotarget. 2017 Jun 29;8(40):67821-67828. doi: https://doi.org/10.18632/oncotarget.18869. PMID: 28978075; PMCID: PMC5620215

54.

Marik PE. Adrenal-exhaustion syndrome in patients with liver disease. Intensive Care Med. 2006;32(2):275–80. https://doi.org/10.1007/s00134-005-0005-5. (Epub 2006 Jan 24 PMID: 16432671).CrossRefPubMed

55.

Levick C, Aspinall RJ. Prevalence and clinical significance of relative adrenal insufficiency in decompensated cirrhosis. J R Coll Physicians Edinb. 2019;49(4):274–6. https://doi.org/10.4997/JRCPE.2019.404. (PMID: 31808451).CrossRefPubMed

56.

Téllez L, Guerrero A. Management of Liver Decompensation in Advanced Liver Disease (Renal Impairment, Liver Failure, Adrenal Insufficiency, Cardiopulmonary Complications). Clin Drug Investig. 2022 Jun;42(Suppl 1):15–23. doi: https://doi.org/10.1007/s40261-022-01149-3. Epub 2022 May 6. PMID: 35522396; PMCID: PMC9205830.

57.

Nandish HK, Arun CS, Nair HR, Gopalakrishna R, Kumar H, Venu RP. Adrenal insufficiency in decompensated cirrhotic patients without infection: prevalence, predictors and impact on mortality. J R Coll Physicians Edinb. 2019;49(4):277–81. https://doi.org/10.4997/JRCPE.2019.405. (PMID: 31808452).CrossRefPubMed

58.

Piano S, Favaretto E, Tonon M, Antonelli G, Brocca A, Sticca A, Mareso S, Gringeri E, Scaroni C, Plebani M, Russo FP, Burra P, Cillo U, Angeli P. Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2020;18(5):1188-1196.e3. https://doi.org/10.1016/j.cgh.2019.09.035. (Epub 2019 Oct 4 PMID: 31589973).CrossRefPubMed

59.

Wentworth BJ, Siragy HM. Adrenal Insufficiency in Cirrhosis. J Endocr Soc. 2022 Jul 29;6(10):bvac115. doi: https://doi.org/10.1210/jendso/bvac115. PMID: 36033971; PMCID: PMC9408036.

60.

Malespin M, Nassri A. Endocrine Diseases and the Liver: An Update. Clin Liver Dis. 2019;23(2):233–46. https://doi.org/10.1016/j.cld.2018.12.006. (Epub 2019 Mar 8 PMID: 30947874).CrossRefPubMed

61.

Jeong HM, Kim DJ. Bone Diseases in Patients with Chronic Liver Disease. Int J Mol Sci. 2019 Aug 31;20(17):4270. doi: https://doi.org/10.3390/ijms20174270. PMID: 31480433; PMCID: PMC6747370

62•.

Yang YJ, Kim DJ. An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia. Int J Mol Sci. 2021 Mar 5;22(5):2604. doi: https://doi.org/10.3390/ijms22052604. PMID: 33807573; PMCID: PMC7961345. Important review of the musculoskeletal consequences of chronic liver disease

63.

Guañabens N, Parés A. Osteoporosis in chronic liver disease. Liver Int. 2018;38(5):776–85. https://doi.org/10.1111/liv.13730. (Epub 2018 Mar 25 PMID: 29479832).CrossRefPubMed

64.

Compston JE, McClung MR, Leslie WD. Osteoporosis Lancet. 2019;393(10169):364–76. https://doi.org/10.1016/S0140-6736(18)32112-3. (PMID: 30696576).CrossRefPubMed

65.

Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. American association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(Suppl 1):1–46. https://doi.org/10.4158/GL-2020-0524SUPPL. (PMID: 32427503).CrossRefPubMed

66.

Polito A, Barnaba L, Ciarapica D, Azzini E. Osteosarcopenia: A Narrative Review on Clinical Studies. Int J Mol Sci. 2022 May 17;23(10):5591. doi: https://doi.org/10.3390/ijms23105591. PMID: 35628399; PMCID: PMC9147376

67.

Vaishnav B, Tambile R, Minna K, Addepalli S, Wadivkar A, Pailla R, Thakkar N, Balem S. Study of Gonadal Hormones in Males With Liver Cirrhosis and Its Correlation With Child-Turcotte-Pugh and Model for End-Stage Liver Disease Scores. Cureus. 2023 Jan 21;15(1):e34035. doi: https://doi.org/10.7759/cureus.34035. PMID: 36814749; PMCID: PMC9940619

Titel: Endocrinology for the Hepatologist
verfasst von: Scott Isaacs
Arabella Isaacs
Publikationsdatum: 18.01.2024
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 1/2024
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-024-00639-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Endocrinology for the Hepatologist

Abstract

Purpose of review

Recent findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

TIPS for Refractory Ascites and Hepatic Hydrothorax

Secondary Sclerosing Cholangiopathies

Cholestatic Pruritus: Pathophysiology, Current Management Approach, and Emerging Therapies

Prophylaxis and Treatment of Bacterial Infections in Cirrhosis

Sarcopenia and Frailty in Advanced Liver Disease Patients: A Comprehensive Review

Non-Cirrhotic Portal Hypertension: an Overview

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Update Innere Medizin